Skip to main content
Premium Trial:

Request an Annual Quote

Illumina: Alex Aravanis, Phil Febbo, Steven Barnard

Alex Aravanis has resigned as chief technology officer of Illumina, and Phil Febbo has resigned from the role of chief medical officer. Steven Barnard, Illumina's VP and head of global advanced science, has taken over the role of CTO. He joined Illumina in 1998 as its first scientist and fourth employee and has held a variety of leadership positions within the company's R&D organization. He holds a PhD in chemistry from Tufts University and a bachelor's degree in chemistry from Connecticut College.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.